Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Mar 1;109(3):718-724.
doi: 10.3324/haematol.2023.283931.

Talquetamab in multiple myeloma

Lawrence Liu  1 , Amrita Krishnan  2
Affiliations

Talquetamab in multiple myeloma

Lawrence Liu et al. Haematologica. .

Abstract

Initial results of the phase I trial of talquetamab, a bispecific antibody targeting GPRC5D and CD3, were reported in December of 2022 for the treatment of relapsed or refractory multiple myeloma in the fourth line or later setting. It demonstrated a similar efficacy profile and durability of response to teclistamab, the first bispecific antibody therapy to be approved in multiple myeloma. Additionally, it has less infections than teclistamab but demonstrates unique class-specific side effects including skin, oral, and nail-related adverse events. Despite this, it is still a highly efficacious and well-tolerated therapy that will add to the armamentarium of therapeutics against heavily pretreated multiple myeloma.

PubMed Disclaimer

References

    1. Gill SK, Unawane R, Wang S, Ahn J, et al. . I-OPen: inferior outcomes of penta-refractory compared to penta-exposed multiple myeloma patients. Blood Cancer J. 2022;12(9):138. - PMC - PubMed
    1. Munshi NC, Anderson LD, Shah N, et al. . Idecabtagene vicleucel in relapsed and refractory multiple yeloma. N Engl J Med. 2021;384(8):705-716. - PubMed
    1. Berdeja JG, Madduri D, Usmani SZ, et al. . Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet. 2021;398(10297):314-324. - PubMed
    1. Moreau P, Garfall AL, Van De Donk NWCJ, et al. . Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med. 2022;387(6):495-505. - PMC - PubMed
    1. Chari A, Minnema MC, Berdeja JG, et al. . Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma. N Engl J Med. 2022;387(24):2232-2244. - PubMed

Substances